Literature DB >> 21273030

The safety of synthetic colloid in critically ill patients with severe traumatic brain injuries.

Mypinder S Sekhon1, Vinay K Dhingra, Indeep S Sekhon, William R Henderson, Neilson McLean, Donald E G Griesdale.   

Abstract

PURPOSE: Although 4% albumin is associated with increased mortality in patients with traumatic brain injury (TBI), evidence concerning the safety of synthetic colloids is lacking. We aimed to determine if there is an association between synthetic colloids and mortality in patients with severe TBI.
MATERIALS AND METHODS: A retrospective cohort study of patients with severe TBI was conducted. Data were collected on all intravenous fluids administered during the first 14 days of admission. Multivariable Cox proportional hazards regression was used to model the association between daily cumulative pentastarch quintiles and mortality.
RESULTS: Patients receiving pentastarch had higher Acute Physiology and Chronic Health II scores (23.9 vs 21.6, P < .01), frequency of craniotomy (42.5% vs 21.6%, P = .02), longer duration of intensive care unit stay (12 vs 4 days, P < .01), and mechanical ventilation (10 vs 3 days, P < .01). On unadjusted Cox regression, patients in the highest quintile of cumulative pentastarch administration had a higher rate of mortality compared with those receiving no colloid (hazard ratio, 3.8; 95% confidence interval, 1.2-12.4; P = .03). However, this relationship did not persist in the final multivariable model (hazard ratio 1.0; 95% confidence interval, 0.25-4.1; P = .98).
CONCLUSION: There was no association between cumulative exposure to pentastarch and mortality in patients with severe TBI.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21273030     DOI: 10.1016/j.jcrc.2010.12.001

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  6 in total

Review 1.  Intravenous Fluid Therapy in Traumatic Brain Injury and Decompressive Craniectomy.

Authors:  Hernando Raphael Alvis-Miranda; Sandra Milena Castellar-Leones; Luis Rafael Moscote-Salazar
Journal:  Bull Emerg Trauma       Date:  2014-01

Review 2.  Fluid therapy in neurointensive care patients: ESICM consensus and clinical practice recommendations.

Authors:  Mauro Oddo; Daniele Poole; Raimund Helbok; Geert Meyfroidt; Nino Stocchetti; Pierre Bouzat; Maurizio Cecconi; Thomas Geeraerts; Ignacio Martin-Loeches; Hervé Quintard; Fabio Silvio Taccone; Romergryko G Geocadin; Claude Hemphill; Carole Ichai; David Menon; Jean-François Payen; Anders Perner; Martin Smith; José Suarez; Walter Videtta; Elisa R Zanier; Giuseppe Citerio
Journal:  Intensive Care Med       Date:  2018-03-02       Impact factor: 17.440

3.  Hemoglobin Area and Time Index Above 90 g/L are Associated with Improved 6-Month Functional Outcomes in Patients with Severe Traumatic Brain Injury.

Authors:  Donald E Griesdale; Mypinder S Sekhon; David K Menon; Andrea Lavinio; Joseph Donnelly; Chiara Robba; Indeep S Sekhon; Andrew Taylor; William R Henderson; Alexis F Turgeon; Arun K Gupta
Journal:  Neurocrit Care       Date:  2015-08       Impact factor: 3.210

4.  Fluid therapy in neurotrauma: basic and clinical concepts.

Authors:  Hernando Raphael Alvis-Miranda; Andres M Rubiano; Juan C Puyana; Gabriel Alcala-Cerra; Luis Rafael Moscote-Salazar
Journal:  Rev Health Care       Date:  2014

Review 5.  Traumatic Brain Injury-A Review of Intravenous Fluid Therapy.

Authors:  Armi Pigott; Elke Rudloff
Journal:  Front Vet Sci       Date:  2021-07-09

6.  Multifaceted Benefit of Whole Blood Versus Lactated Ringer's Resuscitation After Traumatic Brain Injury and Hemorrhagic Shock in Mice.

Authors:  Benjamin E Zusman; Patrick M Kochanek; Zachary S Bailey; Lai Yee Leung; Vincent A Vagni; David O Okonkwo; Ava M Puccio; Lori A Shutter; Keri L Janesko-Feldman; Janice S Gilsdorf; Deborah A Shear; Ruchira M Jha
Journal:  Neurocrit Care       Date:  2020-09-04       Impact factor: 3.532

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.